• Je něco špatně v tomto záznamu ?

SMARCB1/INI1-deficient sinonasal carcinoma shows methylation of RASSF1 gene: A clinicopathological, immunohistochemical and molecular genetic study of a recently described entity

J. Laco, M. Chmelařová, H. Vošmiková, K. Sieglová, I. Bubancová, P. Dundr, K. Němejcová, J. Michálek, P. Čelakovský, R. Mottl, I. Sirák, M. Vošmik, A. Ryška,

. 2017 ; 213 (2) : 133-142. [pub] 20161025

Jazyk angličtina Země Německo

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc17023375

The aim of the study was detailed clinicopathological investigation of SMARCB1/INI1-deficient sinonasal carcinomas, including molecular genetic analysis of mutational status and DNA methylation of selected protooncogenes and tumor suppressor genes by means of next generation sequencing (NGS) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). A total of 4/56 (7%) cases of SMARCB1/INI1-deficient carcinomas were detected among 56 sinonasal carcinomas diagnosed over a 19year period using immunohistochemical screening. The series comprised 3 males and 1 female, aged 27-76 years (median 64 years). All tumors arose in the nasal cavity. Three neoplasms were diagnosed in advanced stage pT4. During the follow-up period (range 14-111 months (median 72 months)), three tumors recurred locally, but none of the patients developed regional or distant metastases. Ultimately, two patients died due to the tumor. Microscopically, all tumors consisted of infiltrating nests of polygonal basaloid cells with a variable component of rhabdoid cells with eosinophilic cytoplasm. Immunohistochemically, there was almost diffuse expression of cytokeratins (CK), p16, p40 and p63 in all cases, while expression of CK5/6, CK7 and vimentin was only focal or absent. The detection of NUT gave negative results. In three cases, the absence of SMARCB1/INI1 expression was due to deletion of SMARCB1/INI1 gene. Methylation of SMARCB1/INI1 gene was not found. One tumor harbored HPV18 E6/E7 mRNA. All 12 genes (BRAF, BRCA1, BRCA2, KIT, EGFR, KRAS, NRAS, PDGFRA, PIK3CA, PTEN, RET, and ROS1) tested for mutations using NGS were wild-type. Regarding DNA methylation, all four SMARCB1/INI1-deficient tumors showed methylation of RASSF1 gene by means of MS-MLPA. There was a statistically significant difference in RASSF1 gene methylation between SMARCB1/INI1-deficient and SMARCB1/INI1-positive tumors (p=0.0095). All other examined genes (ATM, BRCA1, BRCA2, CADM1, CASP8, CD44, CDKN1B, CDKN2A, CDKN2B, CHFR, DAPK1, ESR1, FHIT, GSTP1, HIC1, KLLN, MLH1a, MLH1b, RARB, and VLH) were unmethylated. In summary, we described four cases of SMARCB1/INI1-deficient sinonasal carcinoma with detailed clinicopathological data indicating that these tumors can be regarded as a distinct entity with aggressive behaviour. For the first time, we performed analysis of DNA methylation in SMARCB1/INI1-deficient sinonasal carcinomas, reporting on significantly higher methylation of RASSF1 gene in this neoplasm.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17023375
003      
CZ-PrNML
005      
20170908123152.0
007      
ta
008      
170720s2017 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.prp.2016.10.012 $2 doi
035    __
$a (PubMed)28069272
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia. Electronic address: lacoj@lfhk.cuni.cz.
245    10
$a SMARCB1/INI1-deficient sinonasal carcinoma shows methylation of RASSF1 gene: A clinicopathological, immunohistochemical and molecular genetic study of a recently described entity / $c J. Laco, M. Chmelařová, H. Vošmiková, K. Sieglová, I. Bubancová, P. Dundr, K. Němejcová, J. Michálek, P. Čelakovský, R. Mottl, I. Sirák, M. Vošmik, A. Ryška,
520    9_
$a The aim of the study was detailed clinicopathological investigation of SMARCB1/INI1-deficient sinonasal carcinomas, including molecular genetic analysis of mutational status and DNA methylation of selected protooncogenes and tumor suppressor genes by means of next generation sequencing (NGS) and methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA). A total of 4/56 (7%) cases of SMARCB1/INI1-deficient carcinomas were detected among 56 sinonasal carcinomas diagnosed over a 19year period using immunohistochemical screening. The series comprised 3 males and 1 female, aged 27-76 years (median 64 years). All tumors arose in the nasal cavity. Three neoplasms were diagnosed in advanced stage pT4. During the follow-up period (range 14-111 months (median 72 months)), three tumors recurred locally, but none of the patients developed regional or distant metastases. Ultimately, two patients died due to the tumor. Microscopically, all tumors consisted of infiltrating nests of polygonal basaloid cells with a variable component of rhabdoid cells with eosinophilic cytoplasm. Immunohistochemically, there was almost diffuse expression of cytokeratins (CK), p16, p40 and p63 in all cases, while expression of CK5/6, CK7 and vimentin was only focal or absent. The detection of NUT gave negative results. In three cases, the absence of SMARCB1/INI1 expression was due to deletion of SMARCB1/INI1 gene. Methylation of SMARCB1/INI1 gene was not found. One tumor harbored HPV18 E6/E7 mRNA. All 12 genes (BRAF, BRCA1, BRCA2, KIT, EGFR, KRAS, NRAS, PDGFRA, PIK3CA, PTEN, RET, and ROS1) tested for mutations using NGS were wild-type. Regarding DNA methylation, all four SMARCB1/INI1-deficient tumors showed methylation of RASSF1 gene by means of MS-MLPA. There was a statistically significant difference in RASSF1 gene methylation between SMARCB1/INI1-deficient and SMARCB1/INI1-positive tumors (p=0.0095). All other examined genes (ATM, BRCA1, BRCA2, CADM1, CASP8, CD44, CDKN1B, CDKN2A, CDKN2B, CHFR, DAPK1, ESR1, FHIT, GSTP1, HIC1, KLLN, MLH1a, MLH1b, RARB, and VLH) were unmethylated. In summary, we described four cases of SMARCB1/INI1-deficient sinonasal carcinoma with detailed clinicopathological data indicating that these tumors can be regarded as a distinct entity with aggressive behaviour. For the first time, we performed analysis of DNA methylation in SMARCB1/INI1-deficient sinonasal carcinomas, reporting on significantly higher methylation of RASSF1 gene in this neoplasm.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x genetika $x metabolismus $7 D014408
650    _2
$a karcinom $x genetika $x metabolismus $x patologie $7 D002277
650    12
$a metylace DNA $7 D019175
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a vysoce účinné nukleotidové sekvenování $7 D059014
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nádory sinu maxillaris $x genetika $x metabolismus $x patologie $7 D008444
650    _2
$a lidé středního věku $7 D008875
650    _2
$a staging nádorů $7 D009367
650    _2
$a gen SMARCB1 $x genetika $x metabolismus $7 D000071796
650    _2
$a nádorové supresorové proteiny $x genetika $x metabolismus $7 D025521
655    _2
$a časopisecké články $7 D016428
700    1_
$a Chmelařová, Marcela $u Institute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
700    1_
$a Vošmiková, Hana $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
700    1_
$a Sieglová, Kateřina $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
700    1_
$a Bubancová, Ivana $u Institute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
700    1_
$a Dundr, Pavel $u Department of Pathology, Charles University, First Faculty of Medicine and General University Hospital in Prague, Czechia.
700    1_
$a Němejcová, Kristýna $u Department of Pathology, Charles University, First Faculty of Medicine and General University Hospital in Prague, Czechia.
700    1_
$a Michálek, Jaroslav $u Department of Clinical and Molecular Pathology, Palacky University, Faculty of Medicine and Dentistry and University Hospital Olomouc, Czechia.
700    1_
$a Čelakovský, Petr $u Department of Otorhinolaryngology and Head and Neck Surgery, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
700    1_
$a Mottl, Radovan $u Department of Dentistry, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
700    1_
$a Sirák, Igor $u Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
700    1_
$a Vošmik, Milan $u Department of Oncology and Radiotherapy, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
700    1_
$a Ryška, Aleš $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Czechia.
773    0_
$w MED00003712 $t Pathology, research and practice $x 1618-0631 $g Roč. 213, č. 2 (2017), s. 133-142
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28069272 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170908123753 $b ABA008
999    __
$a ok $b bmc $g 1239056 $s 984288
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 213 $c 2 $d 133-142 $e 20161025 $i 1618-0631 $m Pathology, research and practice $n Pathol Res Pract $x MED00003712
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace